How do I convert a hemodynamically stable patient in sinus rhythm with normal electrolytes and adequate renal function from IV amiodarone to oral dofetilide (Tikosyn)?

Converting from IV Amiodarone to Oral Dofetilide (Tikosyn)

You must wait at least 3 months after stopping amiodarone before initiating dofetilide, or until amiodarone plasma levels fall below 0.3 mcg/mL. This is a critical FDA-mandated safety requirement due to amiodarone's extremely long half-life and unpredictable pharmacokinetics 1.

Why This Prolonged Washout Period is Mandatory

Amiodarone has a half-life of approximately 40-60 days and accumulates extensively in tissues. The drug's metabolites persist for months after discontinuation 2. Initiating dofetilide while amiodarone remains in the system creates dangerous additive QT prolongation and substantially increases the risk of torsades de pointes, which already occurs in 0.3-10.5% of dofetilide patients 3.

The FDA drug label explicitly states: "Because of the unpredictable pharmacokinetics of amiodarone, TIKOSYN should not be initiated following amiodarone therapy until amiodarone plasma levels are below 0.3 mcg/mL or until amiodarone has been withdrawn for at least three months" 1.

The Conversion Protocol

Step 1: Discontinue IV Amiodarone

• Stop the amiodarone infusion immediately
• Document the total duration of amiodarone therapy (IV plus any prior oral exposure)

Step 2: Implement the Mandatory Washout Period

• Wait a minimum of 3 months after amiodarone discontinuation
• Alternatively, measure amiodarone plasma levels and wait until they fall below 0.3 mcg/mL
• During this period, use alternative rate control strategies (beta-blockers, calcium channel blockers) if needed 4

Step 3: Prepare for Dofetilide Initiation

Before starting dofetilide, you must:

• Calculate creatinine clearance using the Cockcroft-Gault equation
• Measure baseline QTc (average of 5-10 beats)
• Correct electrolytes: potassium ≥4.0 mEq/L, normal magnesium 4
• Ensure hospital admission with continuous ECG monitoring capability for minimum 3 days 1

Step 4: Dofetilide Dosing Based on Renal Function

Starting dose determination 1:

• CrCl >60 mL/min: 500 mcg twice daily
• CrCl 40-60 mL/min: 250 mcg twice daily
• CrCl 20-39 mL/min: 125 mcg twice daily
• CrCl <20 mL/min: Dofetilide is contraindicated

Contraindications to initiating dofetilide:

• Baseline QTc >440 msec (>500 msec with ventricular conduction abnormalities)
• Heart rate <60 bpm (use QT interval instead of QTc)

Step 5: In-Hospital Monitoring Protocol

• Measure QTc at 2-3 hours after each of the first 5 doses
• If QTc increases >15% from baseline OR exceeds 500 msec (550 msec with bundle branch block):
  • 500 mcg BID → reduce to 250 mcg BID
  • 250 mcg BID → reduce to 125 mcg BID
  • 125 mcg BID → reduce to 125 mcg once daily
• If QTc exceeds 500 msec after the second dose: discontinue dofetilide permanently 1

Step 6: Minimum Monitoring Duration

Continue telemetry for the longer of:

• 3 days minimum, OR
• 12 hours after cardioversion to sinus rhythm 1

Critical Safety Considerations

Common pitfalls to avoid:

• Never attempt rapid switching from amiodarone to dofetilide despite one small retrospective study suggesting 7-day washout in ICD patients 5. This contradicts FDA labeling and guideline recommendations.
• Do not rely on clinical judgment alone—the 3-month washout or plasma level verification is non-negotiable 1
• Remember that patients who received IV amiodarone for <1 week still require the full washout period due to tissue accumulation

Drug interactions requiring dofetilide discontinuation:

• Cimetidine, verapamil, ketoconazole, trimethoprim-sulfamethoxazole, prochlorperazine, megestrol 1, 6

Alternative Approaches During the Washout Period

Since you cannot use dofetilide for 3 months, consider these rhythm control alternatives for your hemodynamically stable patient in sinus rhythm:

1. Continue rate control only with beta-blockers or calcium channel blockers if the patient remains in sinus rhythm 4

2. Consider sotalol if renal function is adequate (requires in-hospital initiation but no amiodarone washout requirement) 4, 7

3. Electrical cardioversion if the patient reverts to atrial fibrillation during the waiting period 8

The bottom line: There is no safe shortcut for converting from amiodarone to dofetilide. The 3-month mandatory washout period exists because both drugs prolong the QT interval through similar mechanisms, and the combination dramatically increases the risk of fatal ventricular arrhythmias. Plan alternative management strategies during this waiting period.